EAACI Congress 2024
BackOAS 7 - Advances in Oral Immunotherapy
Friday 31 May, 16:45 PM -
18:15 PM Valencia, Spain
Bilbao
Oral Abstract Sessions
16:45
Allergen specific IgE is a stronger predictor of remission following Peanut Oral Immunotherapy in children aged 1-10 years
16:57
Exposure-adjusted safety of peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1-3 years (POSEIDON trial)
17:09
Outcomes of low-dose peanut food challenges in preschoolers when initiating peanut oral immunotherapy
17:21
Oral immunotherapy (OIT) in walnut and hazelnut co-allergic patients: ELISA inhibition studies to direct treatment approach
17:33
Increase in maximum tolerated dose and decrease in symptom severity during food challenge in a clinical trial of oral immunotherapy for peanut allergy in children aged 1 to 3 years
17:45
Basophil activation test as a predicting tool for effective Pru p 3 sublingual immunotherapy response in lipid transfer protein allergy
17:57
FERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without OmalizumabFERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without Omalizumab